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Department of Chemical and Biochemical Engineering, The University of Western Ontario,
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ABSTRACT

Despite recent technological advancements in microcomputed tomography (micro-CT) and
contrast agent development, pre-clinical contrast agents are still predominantly iodine-based.
Higher contrast can be achieved when using elements with higher atomic numbers, such as
lanthanides; lanthanides also have x-ray attenuation properties that are ideal for spectral CT.
However, the formulation of lanthanide-based contrast agents at the high concentrations required
for vascular imaging presents a significant challenge. In this work, we developed an erbium-based
contrast agent that meets micro-CT imaging requirements, which include colloidal stability upon
redispersion at high concentrations, evasion of rapid renal clearance, and circulation times of tens
of minutes in small animals. Through systematic studies with poly(ethylene glycol) (PEG)poly(propylene

glycol),

PEG-polycaprolactone,

and

PEG-poly(L-lactide)

(PLA)

block
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copolymers, the amphiphilic block copolymer PEG114-PLA53 was identified to be ideal for
encapsulating oleate-coated lanthanide-based nanoparticles for in vivo intravenous administration.
We were able to synthesize a contrast agent containing 100 mg/mL of erbium that could be
redispersed into colloidally stable nanoparticles in saline after lyophilization. Contrast
enhancement of over 250 HU was achieved in the blood pool for up to an hour, thereby meeting
the requirements of live animal micro-CT.

KEYWORDS
contrast agent, lanthanides, nanoparticles, micro-CT, polymer self-assembly

INTRODUCTION
With the ultimate goal of developing methods to treat human disease, small animal models are
used extensively in cardiovascular, orthopedic, and cancer research.1-3 The advantages of using
small animals include short gestation times, low maintenance costs and ease of genetic
manipulation.4 In order to study disease at scales suitable for small animals, high-resolution
imaging techniques (i.e., micro-imaging) have been developed; these include micro magnetic
resonance imaging,5,

6

micro positron emission tomography,7 micro-ultrasound,8,

9

and micro

computed tomography (micro-CT).10 Among these, micro-CT has been the most utilized, based on
scientific publications in the last five years.
Micro-CT’s ubiquity is attributable to the fact that the modality is quantitative, threedimensional, non-destructive, fast and cost-effective. Contrast in micro-CT is derived from the
differential attenuation of x-rays by various tissues. Unfortunately, soft tissues, which have similar
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densities, have little differential CT contrast and exogenous agents are required to provide contrast.
For example, to image the vasculature, x-ray attenuating contrast agents are injected intravenously
to “opacify” the vessels during the acquisition of the micro-CT scan. With these contrast agents,
vascular imaging by micro-CT can potentially be utilized to reliably track the development of
blood vessels during the process of angiogenesis and in studying the effect of novel therapies for
re-vascularization.11 For human imaging, CT contrast agents are typically small iodinated
molecules, which are cleared within a few minutes through the renal system. However, micro-CT
scan times can be as long as tens of minutes and successful imaging of the vasculature requires the
use of contrast agents that clear from the blood over extended time periods. These agents are
referred to as “blood pool” contrast agents.
Several CT blood pool contrast agents are available commercially for in vivo small animal
research.12, 13 These have been made possible by advances in nanotechnology and consist of
particles large enough to evade immediate renal clearance (i.e. > 10 nm).14 Initially, commercially
available nanoparticle-based blood-pool contrast agents were iodine-based to take advantage of
the strong attenuation of iodine at low energies (k-edge = 33.2 kEv) and included Fenestra VC
(containing 50 mg/mL of iodine) and eXia 160 XL (containing 160 mg/mL of iodine).13, 15 More
recently gold-based agents have been developed (e.g. AuroVist 15 nm, containing 200 mg/mL of
gold), which take advantage of the high density of gold.16 These agents have been developed with
the intent to deliver a high loading of metal (x-ray attenuator) in a small volume of contrast agent
and thereby to provide higher contrast between the vessels and surrounding tissue.
Another class of metals appropriate for CT contrast agents is the lanthanides. These elements
are of particular interest because they have k-edges near the average energies used in micro-CT
(between 80 kVp and 120 kVp). This property makes the lanthanides ideally suited to use with
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specialized micro-CT techniques that take advantage of the spectral properties of materials, such
as dual-energy imaging and spectral CT. Of the lanthanides, gadolinium has been used most
extensively as a contrast agent for magnetic resonance imaging (MRI). Polymer particles decorated
with gadolinium, such as the chelated derivative of diethylenetriaminepentaacetic acid and Gd(III)
on a cross linked polymer nanogel, have been synthesized and used for vessel imaging of mice,
but have Gd loading that is too low for CT imaging (typically < 0.5 mg/mL).17-19
Lanthanide-based nanoparticles have also been explored for imaging, largely due to their
abilities to alter proton relaxation times in MRI in the case of gadolinium20, 21 or their photon
upconversion capabilities in the case of NaLnF4 (where Ln is a lanthanide and the system is codoped).22-24 However, such particles are usually synthesized with hydrophobic ligands,25 making it
challenging to disperse them with high stability in blood. Chatterjee et al. achieved this by coating
lanthanide-based nanoparticles with polyethyleneimine, reaching concentrations of 4.4 mg/mL
(used subcutaneously for upconversion luminescence imaging).22 Budijono et al. explored the
encapsulation of lanthanide-based nanoparticles in block copolymer assemblies, and demonstrated
the stability of these assemblies in serum media at low concentrations (< 1 mg/mL).24 Similary,
Zhu et al. used pH-responsive block copolymers to encapsulate gadolinium-based nanoparticles,
and demonstrated that they could stabilize the nanoparticles in aqueous solution at low
concentrations (< 0.1 mg/mL).21 However, to date only Liu et al., have synthesized a lanthanide
contrast agent with a concentration high enough for micro-CT imaging.26 They encapsulated 70
mg/mL

of

ytterbium

in

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-terminated

poly(ethylene glycol) (PEG) and demonstrated circulation in the blood pool for approximately 20
minutes. However, even higher lanthanide concentrations and blood circulation times are required
for high resolution imaging of the vasculature.
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In this study, we present a simple and systematic method to prepare a lanthanide-based contrast
agent for micro-CT applications, which require high contrast-element loading (> 100 mg/mL
preferred) and long circulation times (ideally > 30 minutes). The high lanthanide concentration
poses a significant challenge, particularly when paired with the need to add polymers, which are
required to achieve long circulation times. Erbium, which we have demonstrated to be an excellent
contrast agent for ex vivo imaging, was selected as the lanthanide.27 Oleate-coated NaErF4
nanoparticles (ErNP) were synthesized and encapsulated into core-shell nanoassemblies via
nanoprecipitation using a series of amphiphilic block copolymers (Figure 1). A sequence of
optimization steps was then performed to identify an ideal polymer, which encapsulates a high
lanthanide content while remaining colloidally stable after redispersion in saline and a mouseblood mimic. Once the ideal polymer was identified, the lanthanide-based contrast agent was
evaluated in vivo over a period of one hour. To our knowledge, this is the first demonstration of
the successful synthesis of an in vivo lanthanide-based blood pool agent that can be dispsersed into
colloidally stable assemblies containing 100 mg/mL of erbium.

Figure 1. Schematic representation of self-assembled erbium-based nanoparticles as a pre-clinical
blood pool contrast agent.
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EXPERIMENTAL SECTION
Materials and General Methods
Reagents were purchased from commercial suppliers as described in the Supporting Information
(SI) and were used without further purification unless otherwise noted. Methods used in the
synthesis and characterization of the materials are also presented in the SI document.

Nanoprecipitation for self-assembly of polymeric nanoparticles containing erbium
nanoparticles
Erbium nanoparticles (ErNP) were synthesized by a previously reported method.28, 29 The ErNP
were self-assembled with purchased poly(ethylene glycol) (PEG)-poly(propylene glycol) (PPG)
triblock copolymers (PEG76-PPG22-PEG76 and PEG137-PPG34-PEG137 where the subscripts indicate
the degree of polymerization of the blocks), or synthesized diblock copolymers of PEG-poly(ecaprolactone)(PCL) (PEG45-PCL20, PEG45-PCL51, PEG114-PCL51, PEG114-PCL97) or PEG-poly(llactide) (PEG45-PLA25, PEG45-PLA52, PEG114-PLA53, PEG114-PLA122).30,

31

ErNP (2 mg) were

dissolved in 0.1 mL of tetrahydrofuran (THF). Separately, 8 mg of copolymer was dissolved in
0.1 mL of THF. These solutions were then combined and added dropwise to 1.8 mL of deionized
water under magnetic stirring. After 1 hour, stirring was stopped and the solution was left uncapped
for 12 hours to allow for organic solvent evaporation. The solutions were then dialyzed against
100 mL of deionized water for 2 days with 5 solvent changes. A 450 nm syringe filter was used to
remove large aggregates and the samples were characterized by dynamic light scattering (DLS),
transmission electron microscopy (TEM) and inductively coupled plasma mass spectrometry (ICPMS).
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Colloidal stability of the polymeric nanoparticles
The sterile polymeric nanoparticles containing ErNP were lyophilized prior to redispersion in
saline. Saline is used as the solvent of the NPs prior to intravenous injection in vivo because it is
isotonic with blood. Therefore the particles must remain colloidally stable in that environment.
DLS size measurements were performed on the redispersed ErNP and the average sizes of the
samples were observed for up to one hour.

Varying the polymer content of the nanoparticles
The polymeric nanoparticles containing ErNP that remained colloidally stable after freezedrying and redispersion in saline, and that encapsulated relatively higher erbium amounts were
selected (PEG114-PLA53). Solutions with varying mass ratios were prepared. Synthesized ErNP
(80 mg dissolved in 4 mL of THF) were added to 320, 160, 80 or 40 mg of PEG114-PLA53 in 4 mL
of THF. These solutions were combined and added dropwise to 100 mL of deionized water under
magnetic stirring. After 1 hour, stirring was stopped and the suspension was left uncapped for 12
hours to allow for organic solvent evaporation. The suspensions were then dialyzed against 500
mL of deionized water for 2 days with 5 solvent changes. A 450 nm syringe filter was used to
remove large aggregates and the samples were characterized by DLS, TEM and ICP-MS. The
samples were lyophilized, sterilized and re-dispersed in 400 µL of saline. 10 µL of the samples
were added to 990 µL of saline or mouse serum mimic for an hour-long time-course DLS study.
The mouse serum mimic was pH 7.4 phosphate buffered saline containing 0.5 µg/mL mouse
immunoglobulins, 1 wt% bovine serum albumin and 0.1 wt% sodium azide. Colloidal stability in
a mouse serum mimic in vitro will serve as an indicator of its stability in vivo. An increase in the
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average size signifies aggregation, which would lead to immune system detection followed by
clearance from the blood pool in vivo.

General micro-CT imaging and analysis methods
Micro-CT images were acquired using the GE Locus Ultra (London, ON) with a protocol
previously used to evaluate contrast agent distribution in vivo.15, 32 Briefly, 1000 views (16 ms per
view) were acquired at 80 kVp, 55 mA over 360° and reconstructed using a cone-beam
reconstruction algorithm. The resulting images have a voxel size of 150 × 150 × 150 µm. Images
were analyzed using MicroView (Parallax Innovations, London, ON) and CT contrast was
reported in Hounsfield Units (HU – a standard linear scale of x-ray attenuation coefficient, where
air = -1000 HU and water = 0 HU). All HU values were measured over a volume of 450 × 450 ×
150 µm.

Micro-CT imaging of erbium-containing polymeric nanoparticles
The relationship between CT contrast and erbium concentration was first determined by microCT. Erbium chloride was diluted in saline at erbium concentrations of 5, 10, 20 and 100 mg/mL,
which acted as calibration standards. The linear regression between CT contrast (in HU) and
erbium concentration was then used to measure the erbium concentrations resulting when 40 mg
of each of the lyophilized 1:1 and 0.5:1 PEG114-PLA53:ErNP formulations were separately
dispersed in 0.2 mL of saline.

Toxicity of the contrast agent
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The 1:1 and 0.5:1 PEG114-PLA53:ErNP mass ratio formulations were tested. Details of these
experiments are described in the SI document. Briefly, an in vitro cell viability assay was done
using C2C12 mouse myoblast cells from Millipore Sigma (Oakville, ON). The cells were
incubated with the contrast agent for 24 hours, after which cell viability was measured using a 3(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
Following in vitro tests, the in vivo toxicity of the contrast agent was evaluated using the dorsal
interscapular subcutaneous tissue of C57BL/6 male mice (25-30 g). All animal studies were
carried out in accordance with the regulations set out by the University of Western Ontario’s
Council on Animal Care, in agreement with the ARRIVE guidelines, and were carried out in
accordance with the U.K. Animals Act, 1986 and associated guidelines.

Intravenous administration of the contrast agent and characterization of distribution in vivo
Five C57BL/6 male mice (25-30 g) were anesthetized initially with 4% isoflurane, and then
1.5% for maintenance, in O2 via a nose cone placed on the snouts of the animals. The tail veins
were catheterized using PE-20 polyethylene tubing. For each mouse, images were first acquired
prior to contrast administration. The contrast agent (0.2 mL) was injected over a period of
3 minutes and three scans were acquired, starting 2 minutes following the end of injection and
ending 60 minutes post injection. The 1:1 PEG114-PLA53:ErNP (mass ratio) was tested in 3 mice
and the 0.5:1 mass ratio formulation was evaluated in 2 mice.

RESULTS AND DISCUSSION
Synthesis and characterization of oleate-coated ErNP
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NaErF4 nanoparticles were synthesized based on a previously reported method.28,

29

DLS

measurements of ErNP in THF reported a Z-average diameter of 50 ± 1 nm and a polydispersity
index (PDI) of 0.18 ± 0.02 (Figure 2a and Figure S2). These results were supported by TEM
imaging (Figure 2b).

Figure 2. a) Volume diameter distribution of ErNP in THF measured by DLS. b) A TEM image of
the oleate-coated ErNP.

Synthesis and characterization of diblock copolymers
The ErNP are oleate-coated, which makes them incompatible with the aqueous blood pool.33 It
was envisioned that by nanoprecipitation of the ErNP with amphiphilic block copolymers,
assemblies containing hydrophobic ErNP in the hydrophobic polymer cores and hydrophilic
stabilizing polymer coronas would be formed (Figure 1). Polymers are relatively easy to prepare,
are colloidally stable even at low concentration, and can be synthesized at different lengths using
various monomers, making them tunable and versatile materials.34 We used PEG as the hydrophilic
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block for its well-known stealth properties against the immune system.35, 36 In lieu of displacing
the oleate on the ErNP surface with polymers,29, 37 we chose to synthesize polymeric micelles by
nanoprecipitation, which is a fast, reproducible, and cost-effective means of suspending
hydrophobic cargo in polar solvents.38 Displacing the oleate on the ErNP surface would favor the
suspension of individual nanoparticles in solution, which is not a requirement in micro-CT.
To identify a carrier that would encapsulate high erbium content while surviving lyophilization
and redispersion in saline, a series of amphiphilic block copolymers was studied (Figure 3, Table
1). Two PEG-PPG-PEG triblock copolymers (commonly referred to as poloxamers), which are
commercially available, cost-effective and are FDA-approved for intravenous administration in
humans, were used to form the polymeric assemblies.39 In addition, several block lengths of PEGPCL and PEG-PLA were synthesized and studied. These diblock copolymers were selected
because they are used clinically as therapeutic drug carriers and are also currently in further clinical
trials.40 The characteristics of the polymeric micelles may change upon varying the copolymer’s
properties (i.e. hydrophobicity of the non-polar block, total block length, and PEG ratio).41

Figure 3. Chemical structures of the amphiphilic block copolymers that were used to form the
polymeric assemblies.

11

Table 1. SEC and 1H NMR characterization results of diblock copolymers. aDetermined by 1H
NMR spectroscopy; bDetermined by SEC.

Copolymer

PEG molar
mass (g/mol)

Monomer
feed (equiv.)

PCL or PLA
molar massa

Mn a

Mn b

Đb

f valuea

PEG76-PPG22-PEG76

6700

-

-

8400

-

-

0.80

PEG137-PPG34-PEG137

12000

-

-

14600

-

-

0.82

PEG45-PCL20

2000

18

2300

4300

5600

1.1

0.47

PEG45-PCL51

2000

35

5800

7800

6300

1.4

0.26

PEG114-PCL51

5000

44

5900

10900

9500

1.1

0.46

PEG114-PCL97

5000

88

11100

16100

10300

1.3

0.31

PEG45-PLA25

2000

22

2300

4300

5200

1.2

0.47

PEG45-PLA52

2000

44

4700

6700

9600

1.1

0.30

PEG114-PLA53

5000

56

4800

9800

10500

1.3

0.51

PEG114-PLA122

5000

111

11000

16000

13500

1.4

0.31

PEG-PCL and PEG-PLA were synthesized using PEG monomethyl ether (2000 or 5000 g/mol)
as the initiator and the block ratios were tuned by varying the equivalents of e-caprolactone or Llactide to achieve PEG mass fractions (f) of approximately 0.5 and 0.3. Methanesulfonic acid was
used as the polymerization catalyst for the synthesis of PEG-PCL, while 1,5,7triazabicyclo[4.4.0]dec-5-ene was used as the catalyst for PEG-PLA synthesis.30, 31 A 1:1 ratio of
catalyst:initiator was used in each case. Characterization of the diblock copolymers was performed
using 1H nuclear magnetic resonance (NMR) spectroscopy (Figures S3-S10) and size exclusion
chromatography (SEC) relative to polystyrene standards (Figures S11-S14) and the results are
summarized in Table 1. Typical signals of PEG, PCL and PLA components were utilized to
calculate the molar ratios of polymerized monomers to PEG and thus the number average
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molecular weight (Mn). The Mn and molar mass dispersities (Đ) were also measured by SEC. The
f values were calculated from the NMR data, as this should provide the most accurate assessment
of the block ratios. The values indicated for the poloxamers were taken from their respective
specification sheets. Overall, the measured Mn values, particularly from NMR spectroscopy, and f
values were in good agreement with the target structures.

Polymer self-assembly and ErNP encapsulation
First, the self-assembly of the block copolymers without ErNPs was investigated. The
copolymers were dissolved in THF then this solution was added to water with stirring. After
removal of THF by dialysis, the resulting nanoassemblies were characterized by DLS and TEM.
The Z-average diameters measured by DLS ranged from 11 to 55 nm (Table 2, Figure S15),
consistent with self-assembly into micelles and TEM images confirmed that solid spherical
particles were formed (Figure S16). The PDIs ranged from 0.1 to 0.6, suggesting that some
copolymers assembled into reasonably monodisperse nanoparticles (PDI < 0.3), whereas others
exhibited a large distribution of sizes (PDI > 0.3). In general, the TEM results were in good
agreement with the volume distributions obtained from DLS, except for both poloxamers (PEG76PPG22-PEG76 and PEG137-PPG34-PEG137). For these poloxamers, the volume distribution in DLS
suggested the presence of small scatterers that could be unassembled copolymers in solution,
whereas the corresponding TEM images showed larger nanoparticles that could result from
aggregation during the drying process.
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Table 2. Z-average diameters and PDIs obtained using DLS for the self-assembly of block
copolymers without ErNP. Each assembly was prepared and measured in triplicate and the error
measurements correspond to the standard deviations on these batches.
Polymer

Z-average diameter (nm)

PDI

PEG76-PPG22-PEG76

11 ± 2

0.6 ± 0.3

PEG137-PPG34-PEG137

17 ± 3

1.0 ± 0.4

PEG45-PCL20

20 ± 1

0.2 ± 0.1

PEG45-PCL51

17 ± 2

0.1 ± 0.1

PEG114-PCL51

18 ± 4

0.1 ± 0.1

PEG114-PCL97

31 ± 4

0.2 ± 0.1

PEG45-PLA25

26 ± 11

0.5 ± 0.2

PEG45-PLA52

29 ± 8

0.4 ± 0.1

PEG114-PLA122

31 ± 10

0.4 ± 0.2

PEG114-PLA53

55 ± 8

0.2 ± 0.1

Having confirmed the self-assembly behavior of the amphiphilic block copolymers alone, ErNPs
were then added. Both the copolymer and ErNP were dissolved in THF and then nanoprecipitated
into water to form suspensions of erbium-containing assemblies. The mass ratio of polymer:ErNP
was 4:1. THF was removed by dialysis, then the suspensions were passed through a 0.45 µm filter.
This filtration served to remove any ErNP that had not been encapsulated and consequently
aggregated, as well as polymer-ErNP assemblies that were too large and would be preferentially
cleared from the blood by the mononuclear phagocytic system (MPS).42, 43 The resulting assemblies
were characterized by DLS and TEM (Figure 4, Table 3). The TEM images showed individual
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ErNP or groups of ErNP across the grid, unlike the oleate-coated ones in Figure 2b, which
displayed no specific organization or aggregation. This suggests the encapsulation of the ErNP
within the amphiphilic block copolymers. It should be noted that the polymers were indiscernible
in the TEM images because of the high contrast from the ErNP. The Z-average diameters that were
measured by DLS ranged from 53 to 183 nm. This also supported the encapsulation of ErNP within
the amphiphilic block copolymers, as these diameters were larger than those of the polymer-only
micelles.
When PEG114-PLA122 or any of the PEG-PCL diblock copolymers were used to form the
assemblies, moderate PDIs (between 0.2 and 0.3) were observed. On the other hand, when using
either poloxamers or the other PEG-PLA diblock copolymers good PDIs (< 0.2) were obtained.
Because the contrast agent was simply required to remain in circulation (i.e. no tissue-targeting
was required), obtaining low PDIs was not of utmost importance; meeting the size requirements
that would allow evasion of immediate renal clearance and preferential uptake by the MPS was
sufficient.
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Figure 4. DLS volume (%) diameter distributions and the corresponding TEM images of polymerencapsulated ErNP using a) PEG76-PPG22-PEG76, b) PEG137-PPG34-PEG137, c) PEG45-PCL20, d)
PEG45-PCL51, e) PEG114-PCL51, f) PEG114-PCL97, g) PEG45-PLA25, h) PEG45-PLA52, i) PEG114PLA53, and j) PEG114-PLA122.
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Table 3. Characterization data for the polymer-encapsulated ErNP obtained from DLS and ICPMS both as initially prepared and after lyophilization followed by resuspension in saline. The
polymer:ErNP mass ratios were 4:1 unless otherwise indicated. Each assembly was prepared and
measured in triplicate and the error measurements correspond to the standard deviations on these
batches. aDetermined by DLS; bDetermined by ICP-MS where 780 µg/L would correspond to
encapsulation of 100% of the Er added during self-assembly.
In water following initial Post-lyophilization and
preparationa
resuspension in salinea Erbium
Polymer
Z-average
(nm)

PDI

Z-average
(nm)

PDI

content (µg/L)b

PEG76-PPG22-PEG76

174 ± 4

0.1 ± 0.1

294 ± 34

0.2 ± 0.1

62 ± 6

PEG137-PPG34-PEG137

176 ± 6

0.1 ± 0.1

212 ± 2

0.2 ± 0.1

232 ± 1

PEG45-PCL20

98 ± 10

0.3 ± 0.1

2145 ± 179

0.2 ± 0.1

377 ± 25

PEG45-PCL51

82 ± 2

0.3 ± 0.1

3204 ± 416

0.2 ± 0.1

506 ± 3

PEG114-PCL51

53 ± 5

0.3 ± 0.1

1057 ± 32

0.6 ± 0.1

596 ± 21

PEG114-PCL97

84 ± 1

0.2 ± 0.1

2861 ± 9

0.4 ± 0.5

732 ± 22

PEG45-PLA25

165 ± 2

0.1 ± 0.1

192 ± 4

0.5 ± 0.1

407 ± 2

PEG45-PLA52

151 ± 2

0.2 ± 0.1

1597 ± 83

0.4 ± 0.1

149 ± 1

PEG114-PLA122

130 ± 2

0.2 ± 0.1

301 ± 13

0.4 ± 0.1

339 ± 4

PEG114-PLA53

154 ± 2

0.1 ± 0.1

134 ± 1

0.2 ± 0.1

599 ± 3

PEG114-PLA53 (2:1)

180 ± 3

0.2 ± 0.1

180 ± 6

0.1 ± 0.1

583 ± 28

PEG114-PLA53 (1:1)

179 ± 4

0.2 ± 0.1

171 ± 3

0.2 ± 0.1

607 ± 16

PEG114-PLA53 (0.5:1)

183 ± 3

0.1 ± 0.1

185 ± 5

0.2 ± 0.1

533 ± 32

17

Redispersion and characterization of the lyophilized polymer-encapsulated ErNP
Because the polymer-encapsulated ErNP were prepared by nanoprecipitation at low
concentrations in water, the sample had to be lyophilized then redispersed at higher concentrations.
The ability to lyophilize and resuspend the assemblies is also advantageous for their long-term
storage. Dried samples were redispersed in 0.9% saline, which is isotonic with blood, and the Zaverage diameters of the assemblies were measured by DLS (Table 3). No filtration was performed
after redispersion. In addition, because colloidal stability of the contrast agent in its administration
medium is required, the Z-average diameters of the redispersed ErNP-loaded assemblies were also
observed by DLS over 60 minutes.
Relative to the pre-lyophilized diameters, minimal changes occurred for the PEG137-PPG34PEG137, PEG45-PLA25, and PEG114-PLA53 assemblies, while the remainder redispersed in saline at
much larger hydrodynamic diameters, suggesting that they were aggregated. For example, the
PEG76-PPG22-PEG76 assemblies, which initially had a Z-average hydrodynamic diameter of 174 ±
4 nm had a diameter of 294 ± 34 nm after redispersion in saline, while the PEG137-PPG34-PEG137
assemblies, which were initially 176 ± 6 nm, were redispersed in saline at 212 ± 2 nm (Figure
S17). Given the very similar f values for these polymers, the larger PEG block is likely capable or
better stabilizing the particles. All PEG-PCL assemblies redispersed in saline as micrometer-sized
particles, which was undesirable, as these particles would be rapidly cleared by the MPS (Figure
S18). The colloidal instabilities of PEG-PCL assemblies may result from PCL’s high
hydrophobicity or crystallinity. The PEG45-PLA52 assemblies also redispersed as microparticles
and PEG114-PLA122 assemblies redispersed at an increased Z-average diameter of 301 ± 13 nm
compared to an initial diameter of 130 ± 2 nm (Figure S19). Both of these copolymers had low f
values of ~0.3, which may contribute to their poor stability to redispersion. However, PEG45-PLA25
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and PEG114-PLA53 assemblies retained Z-average diameters of 192 ± 4 and 134 ± 1 nm after
redispersion in saline, similar to their initial diameters of 165 ± 2 and 154 ± 2 nm. Both remained
colloidally stable for up to 60 minutes. This stability may result from their increased f values of
~0.5.
ICP-MS was used to quantify the concentration of erbium that was encapsulated by each system
(Table 3). These measurements were performed on the initially prepared samples after their
filtration. If all of the added erbium had remained dispersed in assemblies less than 0.45 µm in
diameter, the expected erbium concentration of the suspensions would have been 780 µg/L. The
highest erbium content was observed for PEG114-PCL97 at 732 ± 22 µg/L. The second highest
concentration was obtained with PEG114-PLA53 at 599 ± 3 µg/L, then PEG114-PCL51 at 596 ± 21
µg/L. However, out of the assemblies formed by these block copolymers, only PEG114-PLA53
assemblies could be redispersed without a substantial increase in Z-average diameter in saline. The
other block copolymers that allowed size consistency had lower erbium content, with PEG137PPG34-PEG137 at 232 ± 1 ug/L and PEG45-PLA25 at 407 ± 2 µg/L. Decreased erbium content
resulted from the filtration of unencapsulated hydrophobic ErNP that aggregated in water or ErNP
in assemblies larger than 0.45 µm in diameter. Based on this analysis, further studies were
performed with PEG114-PLA53 as it was able to form stable assemblies with high erbium content.

Characterization of the assemblies formed with PEG114-PLA53
The polymer content of the contrast agent does not contribute to the attenuation of x-rays and
hence will not contribute to higher contrast. It does however contribute to the total mass of the
material in solution, and increases viscosity, thereby making administration of the suspension
difficult. Thus, it would be desirable to decrease the polymer:ErNP ratio in the assemblies.
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However, decreasing the polymer content of the assemblies has one drawback, which is the
potential decrease of their stealthiness and immune system evasion.36 To investigate the possibility
of lowering the polymer content of the contrast agent while retaining stability, assemblies were
formed with lower PEG114-PLA53:ErNP mass ratios (from 4:1 to 2:1, 1:1 and 0.5:1). Their colloidal
stabilities at 37 °C in saline and in a mouse serum mimic were studied by DLS (Figure 5). The
serum mimic contained bovine serum albumin and ions at concentrations that are similar to mouse
blood. The proteins can potentially contribute to polymer shedding, and thereby to nanoparticle
aggregation in vitro. In the blood pool of the animal in vivo, polymer shedding leads to the
detection by the immune system and clearance of the nanoparticles from the blood via the liver.35,
36

In the DLS analysis, the proteins generated insignificant scattering that did not interfere with the

analysis of the assemblies (Figure S20-S21). The Z-average diameters for the initially prepared
assemblies ranged from 121-185 nm and did not vary significantly over a period of 60 minutes in
saline or in the mouse blood mimic, indicating that each formulation was sufficiently stable.
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Figure 5. Time-course DLS results at 37 °C for PEG114-PLA53-encapsulated ErNP postlyophilization after redispersion in a) saline and b) mouse serum mimic.

TEM imaging of the assemblies and analyses of their erbium content were also performed.
Denser ErNP cores were observed when the polymer:ErNP ratio was reduced (Figure 6). Thus,
decreasing the availability of polymers favored higher ErNP loading per assembly. ICP-MS results
revealed similar erbium content in the suspensions for all of the mass ratios. Given this, and their
colloidal stability in vitro, all the formulations should demonstrate similar contrast enhancement
values over time once concentrated and administered to the blood pool. However, the concentrated
solutions formed with polymer:ErNP mass ratios of 4:1 and 2:1 had high viscosities that made the
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solutions too challenging to administer in vivo though the 30 G needles. Hence, for subsequent
studies, the assemblies containing PEG114-PLA53:ErNP mass ratios of 1:1 and 0.5:1 were used.
Using pyrene as a fluorescent probe,44 the critical aggregation concentrations (CACs) for these 1:1
and 0.5:1 formulations were measured and compared to that of PEG114-PLA53 assemblies without
ErNP. We found that the CAC of the block copolymer alone was 26 mg/L, whereas those of the
1:1 and 0.5:1 PEG114-PLA53:ErNP formulations were 96 mg/L and 117 mg/L respectively (Figures
S22-S24). Thus, it is evident that the loading of ErNP destabilizes the assemblies to some extent.
Nevertheless, these CAC values are much lower than the concentrations at which they would be
administered, even after dilution into the blood pool.

Figure 6. TEM images of the PEG114-PLA53-encapsulated ErNP using polymer:ErNP mass ratios
of a) 4:1, b) 2:1, c) 1:1, d) 0.5:1.
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Erbium content in ErNP determined via Micro-CT
While ICP-MS was used to detect erbium content before lyophilization, micro-CT was used to
confirm the erbium content of the redispersed and high concentration versions of the contrast
agents. A linear relationship between an element’s concentration and its attenuation of x-rays
exists and does not depend on the specific chemical form of the element. This quantitative property
of micro-CT contrast is one of its advantages as an imaging modality. Calibration standards
containing erbium chloride dissolved in saline at concentrations of 0, 5, 10, 20 and 100 mg/mL of
erbium were scanned. Using linear regression of the measured CT numbers of the standards
(Figure S25), it was determined that 40 mg of the lyophilized 1:1 and 0.5:1 PEG114-PLA53:ErNP
formulations dispersed in 0.2 mL of saline resulted in contrast element concentrations of 48 and
74 mg/mL of erbium respectively. Therefore, 100 mg/mL is achieved when 42 mg of the 1:1
formulation and 27 mg of the 0.5:1 formulation is suspended in 0.1 mL of saline. Micro-CT scans
of the high concentration suspensions verified that 100 mg/mL of erbium was achieved when the
calculated amount of the agent was used (Figure S26). While higher erbium loading can be
achieved with more concentrated solutions, we restricted the experiments to 100 mg/mL in order
to maintain low viscosities for intravenous injection in mice.

Toxicity of the contrast agent
The in vitro and in vivo toxicity of the contrast agent was evaluated prior to its intravenous
administration. Based on MTT assays, greater than 80% viability relative to controls was observed
for the 1:1 polymer to erbium mass ratio formulation up to concentrations of 0.5 mg/mL (Figure
S27). The 0.5:1 polymer to erbium formulation was even less toxic, with greater than 80% viability
up to 1 mg/mL, the highest concentration tested. We also performed subcutaneous injections to
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study the materials in vivo. Subcutaneous tissue has slow absorption and clearance rates of
exogenous materials, which provides an opportunity to study the reaction of tissues to the contrast
agent over prolonged periods. Three-dimensional micro-CT images were obtained in mice before
the subcutaneous injection of the 1:1 and 0.5:1 PEG114-PLA53:ErNP formulations and two weeks
after the administration of the agent. Each scan took 16 seconds to acquire. Representative microCT images for each of the contrast agent formulation injections are shown in Figure S28. The
images show that the contrast agent localized near the injection site for up to two weeks. Gross
examination of the subcutaneous tissue confirmed the presence of some contrast agent near the
injection site. No abnormalities were observed in either the subcutaneous tissue or the dermis
(Figure S29).

Distribution of the contrast agent in vivo
Three-dimensional micro-CT images were obtained in mice before the intravenous
administration of both contrast agent formulations and at three time points following the
administration of the agent. Each scan took 16 seconds to acquire. Representative micro-CT
images for each of the contrast agents are shown in Figure 7. After contrast agent administration,
all the major vessels – particularly the external jugular and axillary veins in Figure 7 – became
clearly visible. For both formulations, there appeared to be no change in contrast in the chambers
of the heart for up to 60 minutes. The contrast in the liver was seen as early as the 2-minute time
point – demonstrated by the ability to distinguish liver from surrounding soft tissue.
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Figure 7. Representative coronal micro-CT images showing the heart, liver, aorta, jugular veins
and bladder of mice that received contrast agent formulated at a) 1:1 and b) 0.5:1 PEG114PLA53:ErNP mass ratios. All times are reported from the completion of the contrast agent injection.
In the 2 minute image in a), the external jugular veins (double arrowheads) and the axillary veins
(arrows) are clearly visible.

Quantitative analysis indicated an increase in blood pool CT number of over 250 HU compared
to pre-contrast values. The bladder was indistinguishable from pre-contrast values, indicating that
the agent was not cleared through the renal system, as expected of materials that exceed the size
of renal fenestrations.14 By the one-hour mark, the liver and the spleen had increased up to 180 ±
15 HU and 278 ± 18 HU, respectively, for the 1:1 formulation, confirming the hypothesis that
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large nanoparticles are cleared through the MPS.35, 36 In the myocardium, the CT number was just
under 100 HU at all time points, which was expected of soft tissue in the absence of contrast
material. As expected, the 0.5:1 polymer:ErNP assemblies demonstrated lower stealth activity, due
to the lower amount of polymer used in the synthesis of the assembly, and were cleared from the
blood more rapidly as indicated by the decreased intensity of the blood pool in the micro-CT
images. Overall, this initial imaging study demonstrates that these new contrast agents can be
dispersed and injected into mice at a concentration sufficient to achieve vascular contrast by microCT in vivo. Furthermore, the particles exhibited sufficient stealth properties to circulate in the
vasculature for at least 1 hour. This suggests the promise of these new lanthanide-based agents for
applications such as dual-energy imaging and spectral CT.

CONCLUSIONS
In this study, by systematically comparing a series of amphiphilic block copolymers composed
of different hydrophobic blocks and different PEG mass fractions, we identified PEG114-PLA53 as
an amphiphilic copolymer that can encapsulate oleate-coated NaErF4 nanoparticles. The PEG114PLA53:ErNP assemblies redispersed into colloidally stable particles in saline after lyophilization
and remained in the blood pool in vivo for at least an hour – a time period that well exceeds live
animal micro-CT requirements. Importantly, we were able to formulate the assemblies at a high
concentration of 100 mg/mL of erbium using PEG114-PLA53. At a delivered dose of 0.2 mL per
mouse, this new contrast agent formulation resulted in the enhancement of blood pool in microCT images (at 80 kVp) by approximately 250 HU (above a soft tissue baseline of 100 HU) for at
least an hour following contrast agent administration. This system should be readily adaptable for
a variety of lanthanides, as the metal can be easily substituted in the oleate-coated NaErF4 while
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retaining very similar properties, suggesting its promise as a new class of contrast agents for microCT as well as other imaging modalities such as MRI and optical imaging, in which lanthanides are
utilized. Future studies will explore further the biodistribution and toxicity profiles of these agents.

SUPPORTING INFORMATION
Additional methods, DLS data, NMR spectra, SEC traces, and time-course size measurements.
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